Gyre Therapeutics Inc. (GYRE) Stock Forecast & Price Target
Gyre Therapeutics Inc. · NASDAQ
$6.03-0.10 (-1.71%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Gyre Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $16.00 to $18.00, so the covering firms are broadly aligned. The average target of $17.00 sits 182% above the current $6.03. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $-0.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Gyre Therapeutics Inc.
As of Jul, 2 of 2 firms rate GYRE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GYRE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.13 – $-0.02 · 3 analysts · -344% YoY
Next period, 3 analysts expect Gyre Therapeutics Inc. to earn $-0.07 a share (range $-0.13 – $-0.02), versus $0.03 a year earlier. Full-year consensus is $-0.29, growing to $-0.12 the year after.
REVENUE · NEXT QUARTER
$26.5M
Range $25.4M – $28.0M · 3 analysts · -13% YoY
Revenue is expected to reach $26.5M (range $25.4M – $28.0M), -13.4% year-over-year. Full-year consensus is $102.3M, rising to $130.8M next year.
Top analysts covering Gyre Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GYRE.
#1
Robert Driscoll
Wedbush · Rank #313
Buy
$27.00+348.1% to target
Overall win rate
30%
+ Follow
#2
Roger Song
Jefferies
Buy
$16.00+165.6% to target
Coverage
—
+ Follow
#3
MK
Matthew Keller
HC Wainwright & Co.
Buy
$18.00+198.8% to target
Coverage
—
+ Follow
#4
SW
Stephen Willey
Stifel
Buy
$28.00+364.7% to target
Coverage
—
+ Follow
#5
CZ
Charles Zhu
LifeSci Capital
Buy
$22.00+265.1% to target
Coverage
—
+ Follow
GYRE stock forecast FAQ
What is GYRE's average 12-month price target?+
The 2 analysts with a live target average $17.00 for Gyre Therapeutics Inc. over the next 12 months, ranging from a $18.00 high to a $16.00 low.
Is GYRE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GYRE?+
The Street-high target is $18.00 (HC Wainwright & Co.), and the Street-low is $16.00 (Jefferies). The average of all 2 active targets is $17.00.
How many Wall Street analysts cover GYRE?+
2 analysts have an active rating on Gyre Therapeutics Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering GYRE?+
Among analysts who currently cover GYRE, Robert Driscoll of Wedbush has the strongest overall Quantellect track record (Rank #313). Their current call is Buy with a $27.00 target.
What is Gyre Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.13 – $-0.02) across 3 analysts. Full-year EPS is projected at $-0.29, rising to $-0.12 the following year.
How much revenue is Gyre Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $26.5M (range $25.4M – $28.0M). Full-year revenue is projected at $102.3M, growing to $130.8M next year.
Have analysts been upgrading or downgrading GYRE lately?+
As of Jul, 2 of 2 firms rate GYRE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GYRE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
